We are live on
!
Find out more
OAM
Oxford Asset Management Portfolio holdings
AUM
$232M
1-Year Est. Return
31%
This Fund
S&P 500
This Quarter
Est. Return
-0.25%
1 Year Est. Return
+31%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$219M
AUM Growth
-$6.3M
(-2.8%)
Cap. Flow
+$7.95M
Cap. Flow
% of AUM
3.64%
Top 10 Holdings %
Top 10 Hldgs %
11.93%
Holding
763
New
327
Increased
77
Reduced
54
Closed
297
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oracle
ORCL
|
+$2.61M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$2.35M |
| 3 |
Canadian Pacific Kansas City
CP
|
+$2.15M |
| 4 |
Teck Resources
TECK
|
+$2.12M |
| 5 |
BlackRock Health Sciences Trust II
BMEZ
|
+$2.08M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CDMO
Avid Bioservices, Inc. Common Stock
CDMO
|
+$3.72M |
| 2 |
Cintas
CTAS
|
+$3.03M |
| 3 |
BCOV
Brightcove, Inc.
BCOV
|
+$2.87M |
| 4 |
Verizon
VZ
|
+$2.3M |
| 5 |
Veeva Systems
VEEV
|
+$2.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.88% |
| 2 | Financials | 13.01% |
| 3 | Technology | 12.25% |
| 4 | Consumer Discretionary | 10.74% |
| 5 | Industrials | 10.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Amneal Pharmaceuticals
AMRX
$5.71B
| $174K | 0.08% |
20,725
-34,801
| -63% | -$290K |
|
377
Acco Brands
ACCO
$402M
| $172K | 0.08% |
+40,995
| New | +$201K |
|
378
Nuveen Churchill Direct Lending
NCDL
$623M
| $170K | 0.08% |
+10,039
| New | +$172K |
|
379
Star Holdings Shares of Beneficial Interest
STHO
$114M
| $169K | 0.08% |
+19,864
| New | +$173K |
|
380
Kura Oncology
KURA
$874M
| $167K | 0.08% |
+25,346
| New | +$198K |
|
381
DraftKings
DKNG
$12B
| $165K | 0.08% |
+4,966
| New | +$204K |
|
|
AVNS
382
DELISTED
Avanos Medical
AVNS
| $161K | 0.07% |
+11,238
| New | +$175K |
|
383
Genco Shipping & Trading
GNK
$1.09B
| $160K | 0.07% |
11,989
-19,556
| -62% | -$277K |
|
384
Knowles
KN
$3.27B
| $160K | 0.07% |
+10,507
| New | +$188K |
|
385
Ecovyst
ECVT
$1.1B
| $159K | 0.07% |
+25,711
| New | +$190K |
|
|
PHX
386
DELISTED
PHX Minerals
PHX
| $158K | 0.07% |
40,045
-3,514
| -8% | -$14K |
|
|
DCH
387
Dauch Corp
DCH
$1.58B
| $157K | 0.07% |
38,545
+25,450
| +194% | +$131K |
|
388
Vestis
VSTS
$1.83B
| $155K | 0.07% |
15,661
-21,785
| -58% | -$289K |
|
|
HUT
389
Hut 8
HUT
$10.6B
| $155K | 0.07% |
13,305
+624
| +5% | +$11.5K |
|
390
EyePoint Inc
EYPT
$1.13B
| $154K | 0.07% |
+28,357
| New | +$198K |
|
391
Pitney Bowes
PBI
$2.33B
| $153K | 0.07% |
16,944
+6,706
| +66% | +$60.8K |
|
392
MasterBrand
MBC
$1.84B
| $153K | 0.07% |
+11,731
| New | +$178K |
|
|
BBNX
393
Beta Bionics
BBNX
$738M
| $153K | 0.07% |
+12,500
| New | +$233K |
|
394
BioCryst Pharmaceuticals
BCRX
$2.51B
| $152K | 0.07% |
20,217
+7,052
| +54% | +$56.9K |
|
395
Certara
CERT
$1.23B
| $148K | 0.07% |
+14,951
| New | +$182K |
|
396
Navient
NAVI
$796M
| $146K | 0.07% |
+11,523
| New | +$157K |
|
397
Bioventus
BVS
$1.17B
| $145K | 0.07% |
+15,838
| New | +$158K |
|
398
Prospect Capital
PSEC
$1.15B
| $144K | 0.07% |
35,052
+15,491
| +79% | +$66.7K |
|
399
C4 Therapeutics
CCCC
$400M
| $138K | 0.06% |
+86,224
| New | +$257K |
|
400
Viemed Healthcare
VMD
$355M
| $138K | 0.06% |
18,937
+6,767
| +56% | +$53.1K |
|
Similar funds
KG
VOMP
TLA
RWS
SC
RWMG
TW
NTIC
Oxford Asset Management's Q1 2025 Portfolio in Review
As of Q1 2025, Oxford Asset Management held 763 positions worth $219M, down 2.8% from $225M the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Oxford Asset Management deployed $7.95M of net new capital in Q1 2025, opening 327 new positions and adding to 77 existing holdings. Its largest new stake was Oracle: 16,001 shares worth $2.24M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 13% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Cintas, an estimated $3.03M trimmed.
- Oxford Asset Management's largest Q1 2025 buy was Oracle: 16,001 shares worth $2.24M.
- Oxford Asset Management added most to NEVRO CORP. in Q1 2025, an estimated $2.05M increase.
- Oxford Asset Management's biggest Q1 2025 reduction was Cintas, cutting an estimated $3.03M.
- Oxford Asset Management fully exited Avid Bioservices, Inc. Common Stock in Q1 2025, selling an estimated $3.72M.
- Oxford Asset Management's ten largest holdings make up 12% of its $219M portfolio in Q1 2025.
- Oxford Asset Management opened 327 new positions and closed 297 in Q1 2025.
- Oxford Asset Management's portfolio value fell 2.8% quarter-over-quarter to $219M.
Based on Oxford Asset Management's 13F filing for Q1 2025, filed 15 May 2025.